Literature DB >> 2407127

Inflammatory exudates in skin windows induced by 1-0-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine.

D M Humphrey1.   

Abstract

Previously identified as a platelet-activating factor, 1-0-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine recently has been described as an inflammatory mediator with vasoactive and leukotactic properties. Histologic studies suggested that the local microvascular effects of this potent acetylated alkyl phosphoglyceride were limited in extent. Also, cytologic characterization of exudates was incomplete in tissue sections. Therefore, skin window chambers were used as an alternate model in which to explore the ability of the active form of this lipid mediator to diffuse in tissue. In addition, skin windows provided a convenient means to characterize the leukocytic exudates. Based on measurements of agonist-induced plasma exudation, the effect of 1-0-hexadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine appeared to be limited to the superficial microvasculature underlying the skin window surface. This interpretation was supported by a brief histologic study that revealed vascular labeling by colloidal carbon mostly in a narrow 150-microns dermal zone beneath chambers containing the phospholipid agonist. Finally, the leukocytic exudate recovered at 3 hours consisted of neutrophils and a small number of eosinophils. Thus the skin window model was useful to further characterize the leukocytic exudate, and it suggested that the potent vasoactive effects of the acetylated alkyl phosphoglyceride were limited by local conditions in tissue so as to produce a highly focused inflammatory response.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2407127      PMCID: PMC1877408     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  19 in total

1.  A rapid method of total lipid extraction and purification.

Authors:  E G BLIGH; W J DYER
Journal:  Can J Biochem Physiol       Date:  1959-08

2.  Phosphorus assay in column chromatography.

Authors:  G R BARTLETT
Journal:  J Biol Chem       Date:  1959-03       Impact factor: 5.157

Review 3.  Role of PAF-acether in the vascular events of inflammation.

Authors:  V Lagente; Z B Fortes
Journal:  Prog Biochem Pharmacol       Date:  1988

Review 4.  Role of prostaglandins in microcirculatory function.

Authors:  G Kaley; T H Hintze; M Panzenbeck; E J Messina
Journal:  Adv Prostaglandin Thromboxane Leukot Res       Date:  1985

5.  Accumulation of eosinophils in response to intracutaneous PAF-acether and allergens in man.

Authors:  E Henocq; B B Vargaftig
Journal:  Lancet       Date:  1986-06-14       Impact factor: 79.321

6.  Studies on the mechanism of interleukin 1 stimulation of platelet activating factor synthesis in human endothelial cells in culture.

Authors:  F Bussolino; F Breviario; M Aglietta; F Sanavio; A Bosia; E Dejana
Journal:  Biochim Biophys Acta       Date:  1987-01-19

7.  Microvascular function in skin windows.

Authors:  D M Humphrey; C Cavanaugh
Journal:  Am J Pathol       Date:  1987-03       Impact factor: 4.307

8.  Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor.

Authors:  D M Stafforini; T M McIntyre; M E Carter; S M Prescott
Journal:  J Biol Chem       Date:  1987-03-25       Impact factor: 5.157

9.  Characterization of cutaneous vascular permeability induced by platelet-activating factor in guinea pigs and rats and its inhibition by a platelet-activating factor receptor antagonist.

Authors:  S B Hwang; C L Li; M H Lam; T Y Shen
Journal:  Lab Invest       Date:  1985-06       Impact factor: 5.662

10.  Inhibition of PAF-induced systemic responses in the rat, guinea pig, dog and primate by the receptor antagonist SRI 63-441.

Authors:  D A Handley; J C Tomesch; R N Saunders
Journal:  Thromb Haemost       Date:  1986-08-20       Impact factor: 5.249

View more
  1 in total

Review 1.  PAF. A review of its effects, antagonists and possible future clinical implications (Part II).

Authors:  M Koltai; D Hosford; P Guinot; A Esanu; P Braquet
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.